IndicationNew Join our expert faculty for this important National Broadcast, including a live Q&A session… Bipolar Depression Please see Important Safety Information, including Boxed Presentation, Diagnosis, and Treatment Warnings, below and accompanying full Prescribing This promotional, non-CME program is intended only for healthcare professionals Information. involved in the treatment of adult patients with .

Date: Location: faculty Thursday, August 15, 2013 Novita Wine Bar and Trattoria 860 Franklin Avenue Time: Joseph R. Calabrese, MD Garden City, NY 11530 Professor of 6:30 PM (516) 739-7660 Department of Psychiatry Case Western Reserve University School Meeting Code: of Medicine 19064 Director Mood Disorders Program Attendees will have the option to accept the Sunovion-provided food and beverage Department of Psychiatry service, opt out of all food and beverage, or purchase their own food and beverage. University Hospitals Case Medical Center Cleveland, OH Gary S. Sachs, MD Program Objectives: Founder • address key challenges in the diagnosis and management of bipolar depression Collaborative Care Initiative Rules: Lincoln, MA • e xplore the broader impact of bipolar depression on patients Mauricio Tohen, MD 1-• Withinp resent the relevant codeline, data thefor LATUDA, prism mustnow indicated be shown for monotherapyin and adjunctive green, even on a dark background - Professor and Chairman therapy with either lithium or valproate for the treatment of patients with major Department of Psychiatry itdepressive cannot beepisodes shown associated in white. with (bipolar depression) University of New Mexico Albuquerque, NM 2-Please The seeprism Important should Safety be 40% Information, larger thanincluding the Boxed cap Warnings, below and accompanying height of the full letter Prescribing A. Information. Faculty are consultants of 3- TypefaceSeating used: Interstate is limited, Light Condensed, so register 7 or 8 pt now. Sunovion Pharmaceuticals Inc. Enter the provided meeting code at www.sunovionmeetings.com. Registration is preferred. There is no cost to attend this meeting. For additional program information, call (866) 801-0824; reference the provided meeting code.

Important Safety Information for lATUDA 140% larger than “A”WARNINGS: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; AND SUICIDAL THOUGHTS AND BEHAVIORS • Elderly patients with dementia-related psychosis treated with drugs are at an increased risk of death. LATUDA is not approved for use in patients with dementia-related psychosis. A• Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. LATUDA is not approved for use in patients under the age of 18 years. Please see additional Important Safety Information, including Boxed Warnings, below and accompanying full Prescribing Information. This promotional non-CME program is sponsored by LATUDALatuda® andand are registeredregistered trademarks trademarks of ofDainippon Dainippon Sumitomo Sumitomo Pharma Pharma Co., Co.Ltd. Ltd. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary ofSunovion Dainippon Pharmaceuticals Sumitomo Pharma Inc. Co., is a Ltd. U.S. ©2013 subsidiary Sunovion of Dainippon Pharmaceuticals Sumitomo Inc. PharmaAll rights Co. reserved. Ltd. 7/13 LAT424-13 © 2010 Sunovion Pharmaceuticals Inc. PROPERTY OF SUNOVION PHARMACEUTICALS INC. PROPRIETARY AND NONTRANSFERABLE. NOT FOR FURTHER DISSEMINATION.